903
Views
0
CrossRef citations to date
0
Altmetric
Case Report

First report of acute promyelocytic leukemia in a patient with Wilson’s disease: contemporary discussion of a management challenge

, , ORCID Icon, ORCID Icon, &
Article: 2252649 | Received 30 Jan 2023, Accepted 23 Aug 2023, Published online: 29 Aug 2023

References

  • Bearn AG. Wilson's disease: hepatolenticular degeneration. Postgrad Med J. 1956;32(372):477–481.
  • Maeda S, Matsubara H, Hiejima E, et al. Acute lymphoblastic leukemia in a girl with Wilson's disease. Pediatr Int. 2014;56(4):626–629.
  • Moini M, To U, Schilsky ML. Recent advances in Wilson disease. Transl Gastroenterol Hepatol. 2021;6:21.
  • Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American association for the study of liver diseases. Hepatology. 2023;77(4):1428–1455.
  • Chaudhry HS, Anilkumar AC. Wilson disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
  • Josephat F, Pruett E. Acute promyelocytic leukemia with t(15;17): a case study. MLO Med Lab Obs. 2012;44(7):22–24.
  • Petruzzelli R, Mariniello M, De Cegli R, et al. TFEB regulates ATP7B expression to promote platinum chemoresistance in human ovarian cancer cells. Cells. 2022;11(2).
  • Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–e366.
  • Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643.
  • Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128(4):488–496.
  • Gilman PA, Holtzman NA. Acute lymphoblastic leukemia in a patient receiving penicillamine for Wilson's disease. JAMA. 1982;248(4):467–468.
  • Clausen JE, Arndal JC, Gram L, et al. Chronic lymphocytic leukaemia after treatment with penicillamine. Lancet. 1978;2(8081):152.
  • Pitman SK, Huynh T, Bjarnason TA, et al. A case report and focused literature review of d-penicillamine and severe neutropenia: A serious toxicity from a seldom-used drug. Clin Case Rep. 2019;7(5):990–994.
  • Harris G. Leukaemia-like appearances in mice given penicillamine. Lancet. 1976;2(7999):1356–1357.
  • Rau AR, Usha M, Mallya P, et al. Cytopenia and bone marrow dysplasia in a case of Wilson's disease. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):433–436.
  • Kay AG. Myelotoxicity of D-penicillamine. Ann Rheum Dis. 1979;38(3):232.
  • Richards AJ, Velvin DS, Whitmore DN, et al. Fatal aplastic anaemia and D-penicillamine. Lancet. 1976;307(7960):P646–P647.